MedTrace Logo

Effect of Rectal Misoprostol in Reducing Intra-operative Blood Loss During Myomectomy

NCT05108597 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-11-05

No results posted yet for this study

Summary

A total of 200 women for elective abdominal myomectomy were randomly allocated into two groups.

100 women in experimental group were administered 400ug Misoprostol (2 tablets of Prosotec®) through the rectal route prior to surgery and 100 were in control group, in which no drug was administered.

Conditions

  • Blood Loss, Surgical
  • Uterine Myoma

Interventions

DRUG

Misoprostol

400ug misoprostol will be administered through rectal route, 1 hour before surgery to assess its effect on intra-operative blood loss during myomectomy

Sponsors & Collaborators

  • Pak Emirates Military Hospital

    lead OTHER

Principal Investigators

  • Salma Nisar · Resident OBGYN

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-04
Primary Completion
2020-03-04
Completion
2020-03-04

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05108597 on ClinicalTrials.gov